PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcmPermissionsJournals.ASM.orgJournalJCM ArticleJournal InfoAuthorsReviewers
 
J Clin Microbiol. 1991 March; 29(3): 498–505.
PMCID: PMC269808

In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Abstract

In a double-blind, randomized trial, 102 healthy elderly subjects were inoculated with one of four preparations: (i) intranasal bivalent live attenuated influenza vaccine containing cold-adapted A/Kawasaki/86 (H1N1) and cold-adapted A/Bethesda/85 (H3N2) viruses; (ii) parenteral trivalent inactivated subvirion vaccine containing A/Taiwan/86 (H1N1), A/Leningrad/86 (H3N2), and B/Ann Arbor/86 antigens; (iii) both vaccines; or (iv) placebo. To determine whether local or systemic immunization augmented mucosal immunologic memory, all volunteers were challenged intranasally 12 weeks later with the inactivated virus vaccine. We used a hemagglutination inhibition assay to measure antibodies in sera and a kinetic enzyme-linked immunosorbent assay to measure immunoglobulin G (IgG) and IgA antibodies in sera and nasal washes, respectively. In comparison with the live virus vaccine, the inactivated virus vaccine elicited higher and more frequent rises of serum antibodies, while nasal wash antibody responses were similar. The vaccine combination induced serum and local antibodies slightly more often than the inactivated vaccine alone did. Coadministration of live influenza A virus vaccine did not alter the serum antibody response to the influenza B virus component of the inactivated vaccine. The anamnestic nasal antibody response elicited by intranasal inactivated virus challenge did not differ in the live, inactivated, or combined vaccine groups from that observed in the placebo group not previously immunized. These results suggest that in elderly persons cold-adapted influenza A virus vaccines offer little advantage over inactivated virus vaccines in terms of inducing serum or secretory antibody or local immunological memory. Studies are needed to determine whether both vaccines in combination are more efficacious than inactivated vaccine alone in people in this age group.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol. 1980 Dec;112(6):798–811. [PubMed]
  • Belshe RB, Van Voris LP, Bartram J, Crookshanks FK. Live attenuated influenza A virus vaccines in children: results of a field trial. J Infect Dis. 1984 Dec;150(6):834–840. [PubMed]
  • Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis. 1983 Jul-Aug;5(4):737–747. [PubMed]
  • Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet. 1984 Mar 31;1(8379):705–708. [PubMed]
  • Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986 Jul;24(1):157–160. [PMC free article] [PubMed]
  • Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol. 1986 Jan;23(1):66–72. [PMC free article] [PubMed]
  • Clements ML, O'Donnell S, Levine MM, Chanock RM, Murphy BR. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun. 1983 Jun;40(3):1044–1051. [PMC free article] [PubMed]
  • Clements ML, Tierney EL, Murphy BR. Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine. J Clin Microbiol. 1985 Jun;21(6):997–999. [PMC free article] [PubMed]
  • D'Alessio DJ, Cox PM, Jr, Dick EC. Failure of inactivated influenza vaccine to protect an aged population. JAMA. 1969 Oct 20;210(3):485–489. [PubMed]
  • Feery BJ, Evered MG, Morrison EI. Different protection rates in various groups of volunteers given subunit influenza virus vaccine in 1976. J Infect Dis. 1979 Feb;139(2):237–241. [PubMed]
  • Gorse GJ, Belshe RB, Munn NJ. Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases. J Clin Microbiol. 1986 Sep;24(3):336–342. [PMC free article] [PubMed]
  • Gorse GJ, Belshe RB, Munn NJ. Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. J Clin Microbiol. 1988 May;26(5):911–918. [PMC free article] [PubMed]
  • Gross PA, Quinnan GV, Rodstein M, LaMontagne JR, Kaslow RA, Saah AJ, Wallenstein S, Neufeld R, Denning C, Gaerlan P. Association of influenza immunization with reduction in mortality in an elderly population. A prospective study. Arch Intern Med. 1988 Mar;148(3):562–565. [PubMed]
  • Hobson D, Baker FA, Curry RL. Effect of influenza vaccines in stimulating antibody in volunteers with prior immunity. Lancet. 1973 Jul 21;2(7821):155–156. [PubMed]
  • Howells CH, Vesselinova-Jenkins CK, Evans AD, James J. Influenza vaccination and mortality from bronchopneumonia in the elderly. Lancet. 1975 Feb 15;1(7903):381–383. [PubMed]
  • Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis. 1986 Jul;154(1):121–127. [PubMed]
  • Kasel JA, Couch RB, Six HR, Knight V. Antigenicity of licensed whole virion and subvirion influenza vaccines in "high risk" persons. Proc Soc Exp Biol Med. 1976 Apr;151(4):742–747. [PubMed]
  • MacKenzie JS. Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly. Br Med J. 1977 Jan 22;1(6055):200–202. [PMC free article] [PubMed]
  • Murphy BR, Holley HP, Jr, Berquist EJ, Levine MM, Spring SB, Maassab HF, Kendal AP, Chanock RM. Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain. Infect Immun. 1979 Feb;23(2):253–259. [PMC free article] [PubMed]
  • Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun. 1982 Jun;36(3):1102–1108. [PMC free article] [PubMed]
  • Murphy BR, Rennels MB, Douglas RG, Jr, Betts RF, Couch RB, Cate TR, Jr, Chanock RM, Kendal AP, Maassab HF, Suwanagool S, et al. Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun. 1980 Aug;29(2):348–355. [PMC free article] [PubMed]
  • Patriarca PA, Weber JA, Parker RA, Hall WN, Kendal AP, Bregman DJ, Schonberger LB. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA. 1985 Feb 22;253(8):1136–1139. [PubMed]
  • Peters NL, Meiklejohn G, Jahnigen DW. Antibody response of an elderly population to a supplemental dose of influenza B vaccine. J Am Geriatr Soc. 1988 Jul;36(7):593–599. [PubMed]
  • Powers DC, Sears SD, Murphy BR, Thumar B, Clements ML. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol. 1989 Dec;27(12):2666–2671. [PMC free article] [PubMed]
  • Sears SD, Clements ML, Betts RF, Maassab HF, Murphy BR, Snyder MH. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis. 1988 Dec;158(6):1209–1219. [PubMed]
  • Snyder MH, Banks S, Murphy BR. Determination of antibody response to influenza virus surface glycoproteins by kinetic enzyme-linked immunosorbent assay. J Clin Microbiol. 1988 Oct;26(10):2034–2040. [PMC free article] [PubMed]
  • Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE, Habel LA. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine. 1986 Mar;4(1):38–44. [PubMed]
  • Treanor JJ, Roth FK, Betts RF. Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults. J Clin Microbiol. 1990 Mar;28(3):596–599. [PMC free article] [PubMed]
  • Wright PF, Murphy BR, Kervina M, Lawrence EM, Phelan MA, Karzon DT. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun. 1983 Jun;40(3):1092–1095. [PMC free article] [PubMed]
  • Zahradnik JM, Kasel JA, Martin RR, Six HR, Cate TR. Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine. J Med Virol. 1983;11(4):277–285. [PubMed]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)